Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

BioMoti Collaborates with Global Pharmaceutical Company to Develop Ovarian Cancer Treatment

Appoints Dr John Beadle as Chairman

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BioMoti Ltd today announces an agreement with a global pharmaceutical company to collaborate on the development of its lead ovarian cancer candidate, BMT101, to clinical phase 2a proof-of-concept.

The collaboration agreement provides access to the partner company’s expertise including its proprietary commercial manufacturing technology and an option for the global pharmaceutical company to license BMT101 in specific territories.

BMT101, BioMoti’s lead candidate for the unmet need in ovarian cancer, is a new type of tumor-targeted treatment consisting of CD95-coated long-acting paclitaxel-loaded microparticles. BMT101 has shown very encouraging preclinical proof-of-concept results compared to the clinical standard-of-care, paclitaxel, including over 10-fold increases in drug concentration in tumors, 65-fold reductions in tumor burden, a 4-fold increase in survival, and a reduction in toxicity.

BioMoti also announces that Dr. John Beadle has joined its Board of Directors as Chairman, replacing Dr. Keith Powell who has stepped down. Dr. John Beadle, MBBCh, MBA, brings a wealth of experience and knowledge in the development of clinical-stage biotech companies.

Dr. Beadle was previously founding Chief Executive Officer of PsiOxus Therapeutics, founder and Chief Medical Officer of PowderMed, Entrepreneur-in-Residence at Imperial Innovations, and Vice President of Global Medical Operations at GlaxoSmithKline. To date, he has raised in excess of $150M and realized transaction values in excess of $300M within the biotech industry.

Dr. Davidson Ateh, CEO of BioMoti, said: “We are extremely pleased to have secured a strong development partner with commercial manufacturing experience on similar products to BMT101. The company’s expertise includes developing clinical candidates to market launch, offering a unique opportunity for us to address the significant medical need in the treatment of ovarian cancer patients.”

He added:We are very grateful for the contributions of our departing Chairman, Dr Keith Powell, who has stepped down to focus on other duties. He remains a good friend and trusted advisor. We are delighted to welcome Dr. John Beadle at this crucial stage of our development. John is a remarkable leader within our industry with an impressive track record and whose impact is already being felt as we move forward with the next stages of clinical development.”

Dr. John Beadle, Chairman of BioMoti, said: “I am delighted to join BioMoti at this exciting time as we transition the technology from pre-clinical research into a clinical development program, thus bringing the BioMoti technology one step closer to becoming a treatment for patients with ovarian cancer.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine